Search

Your search keyword '"Lorusso, Domenica"' showing total 1,579 results

Search Constraints

Start Over You searched for: Author "Lorusso, Domenica" Remove constraint Author: "Lorusso, Domenica"
1,579 results on '"Lorusso, Domenica"'

Search Results

451. Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases

452. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial

454. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

455. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel

457. Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

460. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

461. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

463. Advances in laparoscopic surgery for cervical cancer

464. Celio_Supplementary_Table_2 – Supplemental material for Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study

466. BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories

467. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

468. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

470. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

471. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

472. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms

473. Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.

474. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy

475. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17

477. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives

478. Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

479. Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

480. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

481. RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

482. Surveillance in stage I MOGCTs (malignant ovarian germ cell tumors): A MITO prospective study (multicenter Italian trials in ovarian cancer).

483. Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and updated safety data from the phase 3 study ARIEL3.

484. EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ganetespib) compared to platinum-based combination-chemotherapy followed by niraparib in relapsed platinum-sensitive ovarian cancer patients.

485. EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.

488. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

493. Minimally invasive surgery improves short-term outcomes of nerve-sparing radical hysterectomy in patients with cervical cancer: a propensity-matched analysis with open abdominal surgery

495. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study

498. Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC–IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study

499. Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.

500. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) : Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Catalog

Books, media, physical & digital resources